RecruitingPhase 1NCT06383871

A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour

An Open, Multicenter Phase I Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-7058 Monotherapy in Patients With Advanced Solid Tumour With KRAS G12C Mutation

Sponsor

Shandong Suncadia Medicine Co., Ltd.

Enrollment

233 participants

Start Date

Jun 6, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Malignant Tumour

Summary

This study is a multicentre, open phase I clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in subjects with advanced malignant tumour. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-7058.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HRS-7058 capsule/ HRS-7058 tablet for people with advanced malignant tumour. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHRS-7058 capsule/ HRS-7058 tablet

HRS-7058 capsule/ HRS-7058 tablet

Locations(1)

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06383871

Related Trials

A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour

NCT069151422 locations